Med. praxi. 2014;11(1):34-39

QT prolongation caused by medicinal products

MUDr.Michal Prokeš, PharmDr.Josef Suchopár
INFOPHARM a. s.

Long QT interval is associated with increased risk of torsade de pointes (TdP), which is a polymorphic ventricular tachycardia which can

cause sudden death of the patient. TdP emerges at patients with congenital QT prolongation, or TdP appears when QT prolongation

is acquired, which is caused by extrinsic factors, which are usually supported by some inborn dispositions. This paper summarizes current

knowledge of the QT interval prolongation that is caused by drugs and suggests appropriate measures for practicing physicians.

Keywords: QT prolongation, torsade de pointes, adverse drug reactions

Published: February 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Prokeš M, Suchopár J. QT prolongation caused by medicinal products. Med. praxi. 2014;11(1):34-39.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Letsas PK, Filippatos GS, Kounas SP, et al. QT interval prolongation and torsades de pointes in a patient receiving zolpidem and amiodarone. Cardiology 2006; 105: 146-147. Go to original source... Go to PubMed...
    2. Robert R. Genomics and cardiac arrhytmias. J Am Coll Cardiol 2006; 47: 9-21. Go to original source... Go to PubMed...
    3. van Noord C, Eijgelsheim M, Stricker BHC. Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 2010; 70(1): 16-23. Go to original source... Go to PubMed...
    4. Vieweg Wv, Wood MA, Fernandez A, et al. Proarrhytmic Risk with antipsychotic and antidepressant drugs. Drug Aging 2009; 26(12): 997-1012. Go to original source... Go to PubMed...
    5. Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital setting: a scientific statement from the American Heart Assotiation and the American College of Cardiology Foundation. Circulation 2010; 121(8): 1047-1060. Go to original source... Go to PubMed...
    6. Kallergis EM, Goudis CA, Simantirakis EN, et al. Mechanisms, risk factors, and managemetn of acquired long QT syndrome: A comprehensive review. She Scientific World Journal 2012; Article ID 212178, doi: 10.1100/2012/212178. Go to original source... Go to PubMed...
    7. http://www.crediblemeds.org/healthcare-providers/ (vstup 18.11.2013).
    8. Prabhakar M, Krahn AD. Ciprofloxacin-induced acquired long GT syndrome. Heart Rhytm 2004; 1(5): 624-626. Go to original source... Go to PubMed...
    9. Libersa CC, Brique SA, Motte KB, et al. Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol 2000; 49(4): 373-378. Go to original source... Go to PubMed...
    10. Kounas SP, Letsas KP, Sideris A, et al. QT interval prolongation and torsades de pointes due to a coadministration of metronidazol and amiodarone. Pacing Clin Electrophysiol 2005; 28(5): 472-473. Go to original source... Go to PubMed...
    11. Altin C, Kanyilmaz S, Bayasal S, et al. QT interval prolongation due to metronidazole administration. Anadolu Kardiyol Derg. 2011; 11(5): 468-469. doi: 10.5152/akd.2011.120. Epub 2011 Jul 6. Go to original source... Go to PubMed...
    12. Zeuli JD, Wilson JW, Estes L. Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients. Antimicrob Agents chemother 2013; 57(3): 1121-1127. Go to original source... Go to PubMed...
    13. Tisdale JE, Wroblewski HA, Overholser BR, et al. Prevalence of QT interval prolongation in patients admitted do cardiac care units and frequency of subsequent administration of QT interval prolonging drugs. Drug Saf 2012; 35(6): 459-470. Go to original source... Go to PubMed...
    14. Seftchick MW, Adler PH, Hsieh M, et al. The prevalence and factors associated with QTc prolongation among emergency department patients. Ann Emerg Med 2009; 54(6): 763-768. Go to original source... Go to PubMed...
    15. Golzani GH, Dawson NV, Speroff T, et al. Prolonged QTc intervals on admission electrocardiograms: prevanelce and corrrespondence with admission electrolyte abnormalities. Conn Med 2007; 71(7): 389-397. Go to PubMed...
    16. Lubart E, Segal R, Yerovoi A, et al. QT interval disturbvancies in hospitalized elderly patients. Isr Med Assoc J 2009; 11(3): 147-150. Go to PubMed...
    17. Dumontet J, Malyuk R, Kiang G, et al. Corrected QT intervals in newly admitted geriatric psychiatric petients: an examination of risk factors. Can J PSychiatry 2006; 51(6): 371-376. Go to original source... Go to PubMed...
    18. Sijs H, Kowlesar R, Klootwijk PJ, et al. Clinically relevant QTc prolongation due to overriden drug-drug interactions alerts: a restrospective study. Br J Clin Pharmacol 2009; 67(3): 347-354. Go to original source... Go to PubMed...
    19. Molokhia M, Pathak A, Lapeyre-Mestre M, et al. Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in southwest France. Br J Clin Pharmacol 2008; 66(3): 386-395. Go to original source... Go to PubMed...
    20. Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of torsade de pointes. Dtsch Arztebl Int 2011; 108(41): 687-693. Go to original source... Go to PubMed...
    21. Kompendium lékových interakcí INFOPHARM. www. drugagency.cz Elektronická publikace, platná od 1. 10. 2013.
    22. http://www.sukl.cz/fluorochinolony-a-riziko-prodlouzeni-qt-intervalu?highlightWords=fluorochinolony.
    23. Trinkley KE, Lee Page R, Lien H, et al. QT interval prolongation and the risk of torsade de pointes: essentials for clinicians. Curr Med Res Opin. 2013; Sep 23 (Epub ahead of print). Go to original source... Go to PubMed...
    24. Jehle J, Ficker E, Wan X, et al. mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG(K+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells. Br J Pharmacol 2013; 168(5): 1215-1229. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.